BTK-selective degrader NX-5948 reduces inflammation in a murine model of rheumatoid arthritis June 7, 2021
Phase II results presented from study comparing AZD-9567 versus prednisolone in active RA June 3, 2021
Merck & Co.'s [11C]L-235 can be used to assess target engagement of cathepsin K inhibitors June 1, 2021
First-in-human trial of the PET ligand [68Ga]DOTA-Siglec-9 targeting vascular adhesion protein 1 May 27, 2021
RSS